Pluristem to Present at Five Industry and Finance Conferences in May

HAIFA, Israel, May 4, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that its executives will present at the following regenerative medicine and finance conferences during the month of May:

International Society for Pharmaceutical Engineering Europe Annual Conference
Date: 9:10 a.m. on Wednesday, May 6 2015
Location: Frankfurt, Germany
Presentation Title: Flexible Manufacturing of Cell Therapy Product, Challenges and Possible Solutions
Presented by: Nadav Eshkol, Team Leader, Process Development

Israel Advanced Technology Industries Biomed Israel 2015
Date: 5:10 p.m. on Wednesday, May 13 2015
Location: Tel Aviv, Israel
Presentation Title: Regenerative Medicine - When Placental Cells Meet Technology
Presented by: Yaky Yanay, President & COO

Oppenheimer's 16th Annual Israeli Conference
Date: Sunday, May 10 2015
Location: Tel Aviv, Israel
Presentation by: Zami Aberman, Chairman & CEO

Hong Kong-Israel "Game Changing" Investments
Date: Wednesday, May 20 2015
Locations: Hong Kong
Presentation by: Yaky Yanay, President & COO

2015 Capvision "Internet+" Healthcare Investment Summit
Date: Thursday, May 21 2015
Location: Beijing, China
Presentation by: Yaky Yanay, President & COO

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit, the content of which is not part of this press release.

CONTACT: Pluristem Therapeutics Inc. Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109

Source:Pluristem Therapeutics Inc.